Press Releases
Lentiviral vector production is often described as a packaging step, but the final performance depends on the transfer vector, packaging system, envelope, cell-production conditions, purification approach and the way titer is measured. Choosing between a three-plasmid and four-plasmid system is therefore only one part of a broader production decision.
For research teams outsourcing vector production, the useful questions are practical: What material must be provided? What titer is required for the target cells? Is integration desired? Which envelope is appropriate? What QC is needed for the downstream experiment?
A lentiviral packaging system separates the genetic functions required to produce viral particles across multiple plasmids. The transfer plasmid carries the sequence intended for delivery, while packaging and envelope components provide the proteins needed to assemble functional vector particles.
OBiO supports both three-plasmid and four-plasmid production approaches within its custom lentivirus packaging services. The specific setup should be selected according to the transfer vector and project requirements rather than chosen only by plasmid count.
A three-plasmid design typically combines some packaging functions on the same plasmid, reducing the number of DNA components that need to be co-transfected. This can simplify production but should be evaluated in the context of the exact vector backbone.
A four-plasmid design separates additional packaging functions across different plasmids. This is commonly used in modern lentiviral production and gives a more modular production architecture. Plasmid number alone does not determine vector quality, functional titer or downstream performance.
From an SEO perspective the distinction is simple; from an experimental perspective it is not. The correct choice depends on the vector system, biosafety design, target application and supplier process. Researchers should confirm compatibility with the transfer plasmid before sending material for production.
VSV-G is widely used because of its broad tropism and particle stability, but it is not the only option. Alternative envelopes can improve delivery into specific cell types, including hematopoietic and immune-cell populations. OBiO lists multiple envelope options and also supports surface-engineering approaches for specialized applications.
The required amount depends on the target cell, desired MOI, number of cells, number of experimental groups and whether repeat transduction is planned. Difficult-to-transduce primary cells can require substantially more functional vector than an easy cell line.
When the transfer plasmid still needs to be constructed or amplified, the upstream work can be coordinated through custom plasmid services before the packaging run begins.
Lentiviral titer can be reported using different measurement approaches. A functional titer reflects transduction-competent particles under the assay conditions, while nucleic-acid-based methods quantify vector-associated genomes. These measurements answer different questions, so a project should define which titer matters for the downstream experiment before comparing vendors.
QC should match the intended use. Common research-vector checks may include titer and, optionally, additional assays such as ddPCR, sterility, endotoxin, and mycoplasma.Sensitive primary-cell or in vivo studies may require a stricter quality profile than routine cell-line work.
Pooled CRISPR screens often rely on lentiviral delivery because a large cell population must receive guide constructs in a scalable and reproducible way. In those projects, packaging quality, MOI optimization and library representation are linked. OBiO’s CRISPR library screening workflow integrates those decisions with selection, NGS and downstream analysis.
A project can begin with an existing lentiviral transfer plasmid or with the gene sequence if vector construction is also required.
Lentiviral vectors are commonly used for stable genomic integration and cell engineering, while AAV is widely used for in vivo delivery and generally remains episomal. The better platform depends on the target cell or tissue, payload, expression duration and study goal.
Yes. Lentiviral delivery is often selected for primary cells, suspension cells and other models that are difficult to transfect with plasmid DNA.
Yes. OBiO lists multiple envelope options and specialized lentiviral engineering capabilities. Request a lentiviral vector project review.
Request Now